GSK: 2-drug HIV treatment as effective as 3-drug regimen
(CercleFinance.com) - A study showed that GlaxoSmithKline's two-drug regimen to treat HIV was as effective as the three-drug regimen, the British drugmaker said on Wednesday.
ViiV Healthcare, the HIV unit of GSK, said a phase III study showed patients were able to maintain similar rates of viral suppression after switching to its two-drug regimen of dolutegravir plus lamivudine.
The study hence met its primary endpoint for non-inferiority.
The single-pill of dolutegravir plus lamivudine was authorised in the United States earlier this year for the treatment of HIV-1 infection in adults with no antiretroviral treatment history.
It was also authorised in Europe this month.
Copyright (c) 2019 CercleFinance.com. All rights reserved.